KLS · —

Malaysian Pacific Industries Berhad (3867.KL) Stock

$40.30 -0.30% KLS: 3867.KL —

—

Valuation

MetricValue
Price$40.30
Market Cap—
P/E Ratio—
P/B Ratio—
P/S Ratio—
EPS (TTM)—
52-Week High$50.80
52-Week Low$28.00
Dividend Yield—

Financials & Margins

MetricValue
ROE—
ROA—
ROCE—
Gross Margin—
Operating Margin—
Net Margin—
Debt/Equity—
Current Ratio—

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield—
Quick Ratio—
Interest Coverage—
Return 1Y44.58%
Return 3Y74.85%
Return 5Y8.10%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
0090.KLElsoft Research Berhad $0.33 +10.00% 34.50 $233.22M 1.45%
0113.KLMMS Ventures Berhad $0.28 -6.67% -15.50 $60.86M 3.17%
0146.KLJF Technology Berhad $0.74 -5.13% 77.50 $746.95M 0.65%
0166.KLInari Amertron Berhad $2.55 -5.20% 92.33 $10.71B 1.70%
0270.KLNationGate Holdings Berhad $2.11 +15.30% — — 0.00%

About Malaysian Pacific Industries Berhad

—

Malaysian Pacific Industries Berhad is led by CEO Manuel Zarauza Brandulas, employs 6,508 people, headquartered in Ipoh, MY, publicly traded since 2000.

over the past 52 weeks the stock has ranged between $28.00 and $50.80, and currently trades 20.7% below its 52-week high.

Official website: www.mpind.my

Malaysian Pacific Industries Berhad (3867.KL) — frequently asked questions

What is Malaysian Pacific Industries Berhad (3867.KL) stock price today?

Malaysian Pacific Industries Berhad (3867.KL) is currently trading at $40.30, down 0.3% today.

Related — Stocks

USDE StablecoinX Inc. $1.00 -0.01% ALMR Alamar Biosciences, Inc. $29.72 -5.50% AVLN Avalyn Pharma Inc. $27.25 +8.52%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.